CA-HAI-ROBOTICS/SKECHERS
20.2.2024 12:01:30 CET | Business Wire | Press release
Skechers USA, a leading global footwear and apparel company, turns to Hai Robotics ("Hai"), a leading global provider of Automated Storage and Retrieval Systems (ASRS), as they launch their new distribution center in Minato City, Tokyo, Japan. Using Hai’s automated goods-to-person system, Skechers is maximizing warehouse operational efficiency, fulfillment speed, and order accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220854625/en/
A Hai Robotics Autonomous Case-handling Mobile Robot (ACR), one of 69 that pick and transport containers to fulfill orders within Skechers’ distribution center. (Photo: Business Wire)
Hai’s solution was chosen for its ability to condense storage — minimizing real estate needed — and easily adapt to changing demand, resolve labor shortage issues, and support long-term business growth.
Supported by material handling consulting company MHE Solutions, Inc., Skechers built their new facility to keep up with rapidly growing demand in the Japanese market and to advance operations that had historically relied on manually laborious tasks. Manual picking processes had been the standard to fulfill orders, but managing staff shortages coupled with expanding SKU variety contributed to high operating costs with limited outbound picking efficiency and speed. After evaluating several automation providers, Skechers ultimately determined Hai Robotics’ HaiPick System was the ideal solution for dependable and effective automated order fulfillment.
The HaiPick System is dense, adaptable to changes in consumer demand, and easily expandable as operations grow. It seamlessly integrated with other technologies in the facility to help Skechers quickly respond to customer orders. The system has also extended employee productivity while reducing physical demand on staff, helping to alleviate disruption from labor shortages.
Within Skechers’ facility, the HaiPick System covers 139,705 square feet and is operated by 69 HaiPick Autonomous Case-handling Mobile Robots (ACRs), which are integrated with Manhattan Associates' cloud-native warehouse management system (WMS). ACRs are highly intelligent, tall pieces of equipment that autonomously navigate narrow aisles of an ASRS constructed of almost any industry-standard racking or shelving with a vertical reach extending up to 32 feet. The robots pick containers off the shelving — transporting up to 8 at any given time for maximum order-batching efficiency — and deliver them to human-operated workstations.
Skechers’ HaiPick System contains 8 ergonomic workstations where operators receive clear instructions on a screen of the product and quantity to be picked to fulfill an order. The product is then scanned, and the system confirms order accuracy before the operator can proceed to the following order.
The HaiPick System is a vital part of the operational success in Skechers’ new distribution facility, helping Skechers maintain the high level of service and satisfaction their customers enjoy as they continue to grow.
“All automation projects have their challenges, but the Hai team has been a very good partner in maintaining a positive, can-do attitude and remaining committed to doing the right thing for the customer by delivering on their design,” said Sophie Houtmeyers, Vice President of Distribution Operations at Skechers, and Michael Pitt, MHE Solutions. “The Hai ACR system facilitated creative application to maximize both utilization of the warehouse floor space and hard-to-reach vertical storage space in a challenging Japanese warehousing design caused by strict fire codes. It has additionally provided productivity gains that are key to the growth of Skechers in the Japan market.”
“We are honored to help Skechers elevate the operations in their new facility and be a key part in the facility’s ability to quickly reach their customers,” said Brian Reinhart, Chief Revenue Officer at Hai Robotics U.S.A. “We are grateful for the trust that MHE and Skechers have placed in us and thrilled with the success seen so far. We will continue to work closely with MHE Solutions and Skechers to further support their warehouse automation journey and help them go above and beyond in their operational efficiency goals.”
About Hai Robotics
Hai Robotics is a leading global provider of Automated Storage and Retrieval Systems (ASRS) committed to elevating the world’s access to inventory through intelligent, fast, efficient warehouse automation that is more accessible to all facilities.
Their award-winning equipment drives highly flexible ASRS constructed of standard racking and almost any container. Hai Robotics’ solutions maximize vertical storage up to 32+ feet, reduce storage footprints up to 75%, increase workflow efficiency gains up to 4x, and improve order pick accuracy to 99.9%+.
Founded in 2016, Hai Robotics is trusted in 1,100+ projects across 40+ countries and supported by 8 offices globally. For more information, visit HaiRobotics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220854625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom